Evidence map›Paper›PMID 36615455›Full record

ArticleMolecules (Basel, Switzerland)2022

A Novel Curcumin Arginine Salt: A Solution for Poor Solubility and Potential Anticancer Activities.

Adel Al Fatease, Mai E Shoman, Mohammed A S Abourehab, Heba A Abou-Taleb, Hamdy Abdelkader

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Adel Al FateaseDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0002-4608-5949
Mai E ShomanDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Mohammed A S AbourehabDepartment of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.ORCID 0000-0003-1348-6567
Heba A Abou-TalebDepartment of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Merit University (MUE), Sohag 82755, Egypt.ORCID 0000-0001-7655-2088
Hamdy AbdelkaderDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.
King Khalid University · SAMinia University · EGSohag University · EGUmm al-Qura University · SA

Funding

the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by grant code (22UQU4290565DSR50). 22UQU4290565DSR50
6 · The paper itself

Abstract

Curcumin is a natural polyphenolic compound with well-known anticancer properties. Poor solubility and permeability hamper its use as an anticancer pharmaceutical product. In this study, L-arginine, a basic amino acid and a small hydrophilic molecule, was utilized to form a salt with the weak acid curcumin to enhance its solubility and potentiate the anticancer activities of curcumin. Two methods were adopted for the preparation of curcumin: L-arginine salt, namely, physical mixing and coprecipitation. The ion pair or salt was characterized for docking, solubility, DSC, FTIR, XRD, in vitro dissolution, and anticancer activities using MCF7 cell lines. The molecular docking suggested a salt/ion-pair complex between curcumin and L-arginine. Curcumin solubility was increased 335- and 440-fold by curcumin in L-arginine, physical, and co-precipitated mixtures, respectively. Thermal and spectral analyses supported the molecular docking and formation of a salt/ion pair between curcumin and L-arginine. The cytotoxicity of curcumin L-arginine salt significantly improved (p < 0.05) by 1.4-fold, as evidenced by the calculated IC50%, which was comparable to Taxol (the standard anticancer drug but with common side effects).

Indexed as

Antineoplastic AgentsCurcuminArginineHumansMolecular Docking SimulationSodium ChlorideSolubilityAntineoplastic AgentsArginineCurcuminSodium Chloridebreast cancercurcumincytotoxicityL-arginine

Identifiers

PMID36615455
PMCPMC9822184
OpenAlexW4313238136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.